First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice

被引：0

作者：

Naito, Renato ^{[1
]}

Izumi, Kouji ^{[1
]}

Mizokami, Atsushi ^{[1
]}

机构：

[1] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan

来源：

TRANSLATIONAL ANDROLOGY AND UROLOGY | 2020年 / 9卷 / 03期

关键词：

CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; CANCER; PEMBROLIZUMAB; METHOTREXATE; VINBLASTINE; DOXORUBICIN; THERAPY; CHEMOTHERAPY;

D O I：

10.21037/tau.2020.04.08

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

引用

页码：986 / 990

页数：5

共 21 条

[1] IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). [J].

Atkins, Michael B. ;

McDermott, David F. ;

Powles, Thomas ;

Motzer, Robert J. ;

Rini, Brian I. ;

Fong, Lawrence ;

Joseph, Richard Wayne ;

Pal, Sumanta K. ;

Sznol, Mario ;

Hainsworth, John D. ;

Stadler, Walter Michael ;

Hutson, Thomas E. ;

Ravaud, Alain ;

Bracarda, Sergio ;

Suarez, Cristina ;

Choueiri, Toni K. ;

Qiu, Jiaheng ;

Huseni, Mahrukh A. ;

Schiff, Christina ;

Escudier, Bernard J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5] Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 [J].

Bellmunt, Joaquim ;

von der Maase, Hans ;

Mead, Graham M. ;

Skoneczna, Iwona ;

De Santis, Maria ;

Daugaard, Gedske ;

Boehle, Andreas ;

Chevreau, Christine ;

Paz-Ares, Luis ;

Laufman, Leslie R. ;

Winquist, Eric ;

Raghavan, Derek ;

Marreaud, Sandrine ;

Collette, Sandra ;

Sylvester, Richard ;

de Wit, Ronald .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1107-1113

[6] Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 [J].

De Santis, Maria ;

Bellmunt, Joaquim ;

Mead, Graham ;

Kerst, J. Martijn ;

Leahy, Michael ;

Maroto, Pablo ;

Gil, Thierry ;

Marreaud, Sandrine ;

Daugaard, Gedske ;

Skoneczna, Iwona ;

Collette, Sandra ;

Lorent, Julie ;

de Wit, Ronald ;

Sylvester, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) :191-199

[7] Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer [J].

Feld, Emily ;

Harton, Joanna ;

Meropol, Neal J. ;

Adamson, Blythe J. S. ;

Cohen, Aaron ;

Parikh, Ravi B. ;

Galsky, Matthew D. ;

Narayan, Vivek ;

Christodouleas, John ;

Vaughn, David J. ;

Hubbard, Rebecca A. ;

Mamtani, Ronac .

EUROPEAN UROLOGY, 2019, 76 (04) :524-532

[8]

Food and Drug Administration, FDA LIM US TEC KEYTR

[9] Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up [J].

Fradet, Y. ;

Bellmunt, J. ;

Vaughn, D. J. ;

Lee, J. L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D., I ;

Culine, S. ;

Sternberg, C. N. ;

Nam, K. ;

Frenkl, T. L. ;

Perini, R. F. ;

de Wit, R. ;

Bajorin, D. F. .

ANNALS OF ONCOLOGY, 2019, 30 (06) :970-976

[10] IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC). [J].

Galsky, Matt D. ;

Grande, Enrique ;

Davis, Ian D. ;

De Santis, Maria ;

Arija, Jose Angel Arranz ;

Kikuchi, Eiji ;

Mecke, Almut ;

Thastrom, Ann Christine ;

Bamias, Aristotelis .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 →